Kazia Therapeutics Ltd ADR Total Liabilities
Kazia Therapeutics Ltd ADR total liabilities. Based on the latest financial reports, Kazia Therapeutics Ltd ADR (KZIA) has total liabilities worth $14.36 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Kazia Therapeutics Ltd ADR liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Kazia Therapeutics Ltd ADR (1999–2025)
Total liabilities of Kazia Therapeutics Ltd ADR from 1999 to 2025. This chart illustrates how Kazia Therapeutics Ltd ADR's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Kazia Therapeutics Ltd ADR to see how much of total assets are deployed in long-term investments.
Kazia Therapeutics Ltd ADR Competitors by Total Liabilities
The table below lists competitors of Kazia Therapeutics Ltd ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Fecon Foundation Engineering and Underground Construction JSC
VN:FCN
|
Vietnam | ₫7.72 Trillion |
|
GTS Internasional Tbk PT
JK:GTSI
|
Indonesia | Rp72.35 Million |
|
NEW ZEALAND RURAL
F:8UK
|
Germany | €216.89 Million |
|
Panin Sekuritas Tbk
JK:PANS
|
Indonesia | Rp1.28 Trillion |
|
Northview Acquisition Corp
NASDAQ:NVAC
|
USA | $14.30 Million |
|
Aker Technology Co Ltd
TWO:6174
|
Taiwan | NT$407.05 Million |
|
Showbox Corp
KQ:086980
|
Korea | ₩85.54 Billion |
Liability Composition Analysis (1999–2025)
This chart breaks down Kazia Therapeutics Ltd ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Kazia Therapeutics Ltd ADR's balance sheet.
Liquidity & Leverage Metrics
Kazia Therapeutics Ltd ADR Total Liabilities Ratios Explained
Kazia Therapeutics Ltd ADR total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.35 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.73 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kazia Therapeutics Ltd ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kazia Therapeutics Ltd ADR (1999–2025)
The table below shows the annual total liabilities of Kazia Therapeutics Ltd ADR from 1999 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $14.36 Million | -54.55% |
| 2024-06-30 | $31.60 Million | +97.09% |
| 2023-06-30 | $16.03 Million | -8.97% |
| 2022-06-30 | $17.61 Million | -12.96% |
| 2021-06-30 | $20.24 Million | +126.41% |
| 2020-06-30 | $8.94 Million | +27.55% |
| 2019-06-30 | $7.01 Million | -21.55% |
| 2018-06-30 | $8.93 Million | -15.51% |
| 2017-06-30 | $10.57 Million | +566.61% |
| 2016-06-30 | $1.59 Million | -10.77% |
| 2015-06-30 | $1.78 Million | -45.26% |
| 2014-06-30 | $3.25 Million | -16.14% |
| 2013-06-30 | $3.87 Million | 0.00% |
| 2012-06-30 | $3.87 Million | -53.39% |
| 2011-06-30 | $8.31 Million | +35.87% |
| 2010-06-30 | $6.11 Million | -32.58% |
| 2009-06-30 | $9.07 Million | +16.87% |
| 2008-06-30 | $7.76 Million | +15.14% |
| 2007-06-30 | $6.74 Million | +3.39% |
| 2006-06-30 | $6.52 Million | -6.42% |
| 2005-06-30 | $6.97 Million | -76.08% |
| 2004-06-30 | $29.12 Million | +247.33% |
| 2003-06-30 | $8.38 Million | +6.67% |
| 2002-06-30 | $7.86 Million | -56.87% |
| 2001-06-30 | $18.22 Million | +48.26% |
| 2000-06-30 | $12.29 Million | +46.53% |
| 1999-06-30 | $8.39 Million | -- |
About Kazia Therapeutics Ltd ADR
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase I… Read more